Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well lenalidomide works in treating patients with progressive
or recurrent multiple myeloma after a donor stem cell transplant. Lenalidomide may stop the
growth of multiple myeloma by blocking blood flow to the cancer. It may also stimulate the
immune system in different ways and stop cancer cells from growing.